PriceTargets.com logo

Aravive - ARAV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.50
  • Forecasted Upside: 33,565.84%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.04 As of 04/15/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ARAV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aravive Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARAV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARAV

Analyst Price Target is $13.50
▲ +33,565.84% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aravive in the last 3 months. The average price target is $13.50, with a high forecast of $18.00 and a low forecast of $9.00. The average price target represents a 33,565.84% upside from the last price of $0.04.

This chart shows the closing price for ARAV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Aravive. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/22/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/3/2023William BlairDowngradeOutperform ➝ Market PerformLow
8/3/2023HC WainwrightDowngradeBuy ➝ NeutralLow
8/2/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
7/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$18.00Low
7/10/2023BTIG ResearchLower Target$12.00 ➝ $9.00Low
3/15/2023HC WainwrightBoost TargetBuy$7.00 ➝ $12.00Low
2/21/2023HC WainwrightReiterated RatingBuy$7.00Low
2/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00N/A
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$10.00Low
11/13/2022Piper SandlerLower TargetOverweight$6.00 ➝ $2.00Low
11/11/2022Cantor FitzgeraldReiterated RatingOverweightLow
10/27/2022Roth CapitalLower Target$15.00 ➝ $10.00Low
10/26/2022BTIG ResearchLower Target$26.00 ➝ $12.00Low
10/25/2022HC WainwrightLower TargetBuy$26.00 ➝ $7.00Low
6/3/2022Roth CapitalInitiated CoverageBuy$15.00High
5/12/2022Piper SandlerLower Target$9.00 ➝ $6.00Low
4/1/2022Piper SandlerLower Target$14.00 ➝ $9.00High
8/6/2021Piper SandlerLower TargetOverweight$20.00 ➝ $18.00Medium
4/27/2021HC WainwrightReiterated RatingBuy$26.00High
3/8/2021BTIG ResearchInitiated CoverageBuy$26.00High
11/9/2020Piper SandlerLower Target$31.00 ➝ $20.00Medium
11/6/2020HC WainwrightReiterated RatingBuyHigh
9/18/2020William BlairInitiated CoverageOutperformHigh
8/14/2020WedbushReiterated RatingBuy$24.00High
8/13/2020Cantor FitzgeraldReiterated RatingOverweight$30.00Low
8/13/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$31.00Low
7/23/2020HC WainwrightBoost TargetBuy$15.00 ➝ $26.00High
4/30/2020HC WainwrightReiterated RatingBuy$15.00Medium
3/27/2020HC WainwrightLower TargetBuy$25.00 ➝ $15.00High
2/19/2020HC WainwrightReiterated RatingBuy$25.00High
12/20/2019Piper Sandler CompaniesReiterated RatingBuy$31.00Medium
12/20/2019HC WainwrightLower TargetBuy$31.00 ➝ $25.00Low
12/9/2019Cantor FitzgeraldInitiated CoverageOverweight$30.00High
12/3/2019Piper Sandler CompaniesReiterated RatingOverweight$36.00 ➝ $31.00High
12/2/2019Robert W. BairdUpgradeNeutral ➝ OutperformHigh
11/20/2019WedbushBoost TargetPositive ➝ Outperform$12.00 ➝ $28.00Low
11/20/2019HC WainwrightReiterated RatingPositive ➝ Buy$18.00 ➝ $31.00N/A
11/19/2019Piper Sandler CompaniesBoost TargetOverweight$15.00 ➝ $36.00N/A
11/8/2019HC WainwrightReiterated RatingBuyLow
10/10/2019HC WainwrightInitiated CoverageBuy$18.00 ➝ $18.00High
9/27/2019Piper Sandler CompaniesSet TargetBuy$10.00 ➝ $15.00Low
5/13/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$10.00Medium
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/19/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Aravive logo
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $0.04
Low: $0.04
High: $0.04

50 Day Range

MA: $0.04
Low: $0.04
High: $0.04

52 Week Range

Now: $0.04
Low: $0.04
High: $2.46

Volume

N/A

Average Volume

N/A

Market Capitalization

$2.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Aravive?

The following sell-side analysts have issued reports on Aravive in the last year: BTIG Research, Cantor Fitzgerald, HC Wainwright, and William Blair.
View the latest analyst ratings for ARAV.

What is the current price target for Aravive?

2 Wall Street analysts have set twelve-month price targets for Aravive in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 33,565.8%. Cantor Fitzgerald has the highest price target set, predicting ARAV will reach $18.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $9.00 for Aravive in the next year.
View the latest price targets for ARAV.

What is the current consensus analyst rating for Aravive?

Aravive currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ARAV, but not buy more shares or sell existing shares.
View the latest ratings for ARAV.

What other companies compete with Aravive?

Other companies that are similar to Aravive include Altamira Therapeutics, Onconetix, CohBar, Cyclacel Pharmaceuticals and NovaBay Pharmaceuticals. Learn More about companies similar to Aravive.

How do I contact Aravive's investor relations team?

Aravive's physical mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company's listed phone number is (936) 355-1910 and its investor relations email address is [email protected]. The official website for Aravive is www.aravive.com. Learn More about contacing Aravive investor relations.